A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms AGO-OVAR16
- Sponsors Novartis
- 30 Sep 2017 The study has been completed in Spain (End Date:2017-08-24).
- 07 Sep 2017 The study has been completed in Austria.
- 13 Jul 2017 Planned End Date changed from 30 Jun 2017 to 24 Aug 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History